AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

CONTROL BIONICS LIMITED Board/Management Information 2024

Oct 21, 2024

64611_rns_2024-10-21_2d9f8fe6-81ee-46b8-bff6-40845d9f927d.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [177 x 63] intentionally omitted <==

22 October 2024

ASX ANNOUNCEMENT

Appointment of Dr Samuel Straface to CBL Board

The Board of Control Bionics Limited welcomes Dr. Samuel Straface (Ph.D.) as a new independent non-executive director.

Sam is an accomplished Neurophysiologist and has held Senior Executive roles in both Australia and the USA including as President/CEO of multiple Medtech businesses. Sam has extensive experience in the development and commercialisation of premium medical devices and services and will complement the skills of the existing Board in delivering NeuroStrip and other new products to the global market.

This announcement was authorised by CBL Chairman, Roger Hawke.

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Injury, Traumatic Brain Injury and Cerebral Palsy among others. Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography (EMG) signals which are processed on personal computers, smartphones and tablets to generate text, text to speech, email and other computer controlled functions. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics produces the only system to harness three modalities – touch, eye movement and EMG control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. This world first solution allows powered wheelchair users the independence to operate their wheelchairs in the own homes for the first time.